Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

University of California, San Francisco, San Francisco, California, United States
British Journal of Cancer (Impact Factor: 4.84). 04/2006; 94(5):642-6. DOI: 10.1038/sj.bjc.6603012
Source: PubMed


To compare the survival of women with uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC) to those with grade 3 endometrioid uterine carcinoma (G3EC). Demographic, pathologic, treatment, and survival information were obtained from the Surveillance, Epidemiology, and End Results Program from 1988 to 2001. Data were analysed using Kaplan-Meier and Cox proportional hazards regression methods. Of 4180 women, 1473 had UPSC, 391 had CC, and 2316 had G3EC cancers. Uterine papillary serous carcinoma and CC patients were older (median age: 70 years and 68 vs 66 years, respectively; P<0.0001) and more likely to be black compared to G3EC (15 and 12% vs 7%; P<0.0001). A higher proportion of UPSC and CC patients had stage III-IV disease compared to G3EC patients (52 and 36% vs 29%; P<0.0001). Uterine papillary serous carcinoma, CC and G3EC patients represent 10, 3, and 15% of endometrial cancers but account for 39, 8, and 27% of cancer deaths, respectively. The 5-year disease-specific survivals for women with UPSC, CC and G3EC were 55, 68, and 77%, respectively (P<0.0001). The survival differences between UPSC, CC and G3EC persist after controlling for stage I-II (74, 82, and 86%; P<0.0001) and stage III-IV disease (33, 40, and 54; P<0.0001). On multivariate analysis, more favourable histology (G3EC), younger age, and earlier stage were independent predictors of improved survival. Women with UPSC and CC of the uterus have a significantly poorer prognosis compared to those with G3EC. These findings should be considered in the counselling, treating and designing of future trials for these high-risk patients.

Download full-text


Available from: Michael Hendrickson, Jan 20, 2015
  • Source
    • "Type II EC tumors tend to be high grade, poorly differentiated tumors, and are associated with a more aggressive phenotype. Although type II tumors make up only ß20% of all EC cases, they are responsible for a high proportion of EC-related deaths (44%) (Hamilton, et al., 2006). Despite the distinct morphologic and clinical features of the two EC subtypes, most EC patients are treated with the same chemotherapy , without an effective screening strategy in place to distinguish EC subtypes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial cancer (EC) ranks as the sixth common cancer for women worldwide. To better distinguish cancer subtypes and identify effective early diagnostic biomarkers, we need improved understanding of the biological mechanisms associated with EC dysregulated genes. Although there is a wealth of clinical and molecular information relevant to EC in the literature, there has been no systematic summary of EC-implicated genes. In this study, we developed a literature-based database ECGene (Endometrial Cancer Gene database) with comprehensive annotations. ECGene features manual curation of 414 genes from thousands of publications, results from eight EC gene expression datasets, pre-computation of co-expressed long non-coding RNAs and an EC-implicated gene interactome. In the current release, we generated and comprehensively annotated a list of 458 EC-implicated genes. We found the top-ranked EC-implicated genes are frequently mutated in The Cancer Genome Atlas (TCGA) tumor samples. Furthermore, systematic analysis of co-expressed lncRNAs provided insight into the important roles of lncRNA in EC development. ECGene has a user-friendly web interface and is freely available at As the first literature-based online resource for EC, ECGene serves as a useful gateway for researchers to explore EC genetics. This article is protected by copyright. All rights reserved.
    Full-text · Article · Dec 2015 · Human Mutation
  • Source
    • "Notably, 52–70% of type II cancers exhibit extrauterine spread at the time of surgery, compared with 4.6% of Type I tumours (Goff, 2005; Thomas et al, 2008; Yoon et al, 2010). Uterine-serous-carcinoma (USC), is the most biologically aggressive Type II tumour, accounts for 10% of all endometrial cancer and carries the poorest prognosis, with 5-year survival rates as low as 55% (Hamilton et al, 2006). The c-erbB2 gene is a member of the erbB receptor tyrosine kinase family, which consists of four transmembrane glycoproteins: erbB1, erbB2, erbB3 and erbB4. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the role of PIK3CA-mutations as mechanism of resistance to trastuzumab in primary HER2/neu-amplified uterine-serous-carcinoma (USC) cell lines. Fifteen whole-exome-sequenced USC cell lines were tested for HER2/neu-amplification and PIK3CA-mutations. Four HER2/neu-amplified USC (2-harbouring wild-type-PIK3CA-genes and 2-harbouring oncogenic-PIK3CA-mutations) were evaluated in in vitro dose-titration-proliferation-assays, cell-viability and HER2 and S6-protein-phosphorylation after exposure to trastuzumab. USC harbouring wild-type-PIK3CA were transfected with plasmids encoding oncogenic PIK3CA-mutations (i.e., H1047R/R93Q) and exposed to trastuzumab. Finally, trastuzumab efficacy was tested by using two USC xenograft mouse models. Seven out of fifteen (46%) of the USC cell lines were HER2/neu-amplified by fluorescence in situ hybridisation. Within these tumours four out of seven (57%) were found to harbour oncogenic PIK3CA-mutations vs two out of eight (25%) of the HER2/neu not amplified cell lines (P=0.01). HER2/neu-amplified/PIK3CA-mutated USC were highly resistant to trastuzumab when compared with HER2/neu-amplified/wild-type-PIK3CA cell lines (P=0.02). HER2/neu-amplified/PIK3CA wild-type cell lines transfected with oncogenic PIK3CA-mutations increased their resistance to trastuzumab (P<0.0001). Trastuzumab was effective in reducing tumour growth (P=0.001) and improved survival (P=0.0001) in mouse xenografts harbouring HER2-amplified/PIK3CA wild-type USC but not in HER2-amplified/PIK3CA-mutated tumours. Oncogenic PIK3CA mutations are common in HER2/neu-amplified USC and may constitute a major mechanism of resistance to trastuzumab treatment.British Journal of Cancer advance online publication, 1 September 2015; doi:10.1038/bjc.2015.306
    Full-text · Article · Sep 2015 · British Journal of Cancer
  • Source
    • "While early stage, low grade EEC is classically managed by curative hysterectomy, latestage EEC/type II endometrial cancers are associated with significant mortality due to their metastatic spread outwith the uterine corpus (Dedes et al, 2011; DeLeon et al, 2014). Difficulties still exist with the type I/II classification system in terms of prognosis: there is uncertainty as to whether grade 3 EECs should be classified as type I or type II carcinomas (Boruta et al, 2004; Hamilton et al, 2006; Soslow et al, 2007; Voss et al, 2012) while the prognostic significance of tumours with mixed type I/II histology remains the subject of debate (Patsavas et al, 2011; Roelofson et al, 2012). The existence of grade 1 EECs arising in a background of atrophic endometrium also presents difficulties for this dualistic model (Geels et al, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies. This study determined the prognostic significance of preoperative neutrophil:lymphocyte (NLR), platelet:lymphocyte (PLR) and monocyte:lymphocyte (MLR) ratios in endometrial cancer. Clinicopathological and 5-year follow-up data were obtained for a retrospective series of surgically treated endometrial cancer patients (n=605). Prognostic significance was determined for overall (OS) and cancer-specific survival (CSS) using Cox proportional hazards models and Kaplan-Meier analysis. Receiver-operator characteristic and log-rank functions were used to optimise cut-offs. NLR, PLR and MLR associations with clinicopathological variables were determined using non-parametric tests. Applying cut-offs of ⩾2.4 (NLR), ⩾240 (PLR) and ⩾0.19 (MLR), NLR and PLR (but not MLR) had independent prognostic significance. Combining NLR and PLR scores stratified patients into low (NLR-low and PLR-low), intermediate (NLR-high or PLR-high) and high risk (NLR-high and PLR-high) groups: multivariable hazard ratio (HR) 2.51; P<0.001 (OS); HR 2.26; P<0.01 (CSS) for high vs low risk patients. Increased NLR and PLR were most strongly associated with advanced stage (P<0.001), whereas increased MLR was strongly associated with older age (P<0.001). Both NLR and PLR are independent prognostic indicators for endometrial cancer, which can be combined to provide additional patient stratification.British Journal of Cancer advance online publication, 16 June 2015; doi:10.1038/bjc.2015.200
    Full-text · Article · Jun 2015 · British Journal of Cancer
Show more